Esophageal Neoplasms: Clinical Trials

845 completed, 504 unknown, 430 recruiting, 187 terminated. 875 Phase 2, 461 Phase 1, 427 Not applicable, 194 Phase 3, 30 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	875	Completed 300, Unknown 200, Recruiting 165, Terminated 79, Not yet recruiting 55, Active not recruiting 44, Withdrawn 25, Enrolling by invitation 4, Suspended 3
Phase 1	461	Completed 182, Recruiting 94, Terminated 58, Unknown 54, Active not recruiting 37, Not yet recruiting 15, Withdrawn 14, Enrolling by invitation 4, Suspended 3
Not applicable	427	Completed 154, Unknown 107, Recruiting 73, Terminated 35, Not yet recruiting 23, Active not recruiting 18, Withdrawn 11, Enrolling by invitation 4, Suspended 2
Phase 3	194	Completed 62, Unknown 53, Recruiting 40, Not yet recruiting 15, Terminated 11, Active not recruiting 8, Withdrawn 4, Enrolling by invitation 1
Phase 4	30	Completed 12, Unknown 12, Recruiting 2, Terminated 2, Enrolling by invitation 1, Not yet recruiting 1
Early Phase 1	14	Unknown 4, Recruiting 3, Completed 2, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1

Follow Esophageal Neoplasms: new trials by email Literature Review of Esophageal Neoplasms trials Research Report on Esophageal Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Adaptive Neoadjuvant Therapy for Esophageal Cancer Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy	Not applicable	Enrolling by invitation	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	43	2028-03-01	2025-05-25
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel), Simvastatin, Durvalumab - Gastroesophageal Adenocarcinoma	Phase 2	Not yet recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	184	2027-01-01	2026-07-10
Outside the Cage (OTC) Robotic Esophagectomy OTC MIE Esophagectomy - Esophageal Cancer	Phase 1	Not yet recruiting	Centre hospitalier de l'Université de Montréal (CHUM)	31	2027-01-01	2026-03-18
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma	Phase 2	Not yet recruiting	Vanderbilt-Ingram Cancer Center	20	2026-12-31	2026-09-23
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	LG Chem	250	2026-12-01	2026-08-07
Evaluation of the Administration of Artificial Nutrition by Feeding Jejunostomy During Neoadjuvant Treatment on Postoperative Morbidity in the Context of Esophageal or Stomach Cancer Enteral or parenteral nutrition - Esophageal Cancer, Surgery Indication		Recruiting	University Hospital, Bordeaux	670	2026-11-01	2026-05-13
ALDH2 Genetic Testing in East Asian Community Genetic Test Results Return, Alcohol Flushing Education - Healthy Adult, Flushing	Not applicable	Not yet recruiting	Northwestern University	100	2026-11-01	2026-08-11
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function Larotinib - Esophageal Cancer, Advanced Solid Tumor	Phase 1	Withdrawn	Sunshine Lake Pharma Co., Ltd.		2026-10-30	2026-09-28
Modular Robot-Assisted Versus Conventional Minimally Invasive Esophagectomy for Esophageal Cancer Modular Robot-Assisted Esophagectomy, Conventional Minimally Invasive Esophagectomy - Esophageal Cancer	Phase 3	Recruiting	Ruijin Hospital	160	2026-10-15	2026-10-22
A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) anlotinib + PD-1 inhibitor, PD-1 inhibitor - Esophageal Cancer (EC)	Phase 2	Recruiting	Sun Yat-sen University	112	2026-10-12	2026-10-07
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer ICG-guided sentinel lymph node dissection, ICG-guided systematic lymph node dissection - Esophageal Cancer, Sentinel Lymph Node	Phase 3	Not yet recruiting	Fujian Medical University Union Hospital	200	2026-10-01	2026-08-26
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery Esophageal Squamous Cell Carcinoma (ESCC)		Not yet recruiting	Peking University Cancer Hospital & Institute	100	2026-10-01	2026-09-16
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer		Not yet recruiting	Jazz Pharmaceuticals	300	2026-10-01	2026-10-02
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma	Phase 2	Not yet recruiting	Hebei Medical University Fourth Hospital	33	2026-10-01	2026-09-16
REcovery After Cancer Application The RECapp platform - Oesophageal Cancer, Gastric Cancer (Diagnosis)	Not applicable	Not yet recruiting	Karolinska Institutet	250	2026-09-15	2026-08-05
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	BeOne Medicines	30	2026-09-14	2026-10-14
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer	Phase 1	Not yet recruiting	Sutro Biopharma, Inc.	285	2026-09-14	2026-09-08
Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab - Head and Neck Cancer, Non-Small Cell Lung Cancer	Phase 2	Recruiting	Mark Bernard	35	2026-09-09	2026-10-14
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy 18F-G1 - Solid Tumor Malignancies, Hematologic Cancer		Recruiting	Peking University First Hospital	120	2026-09-08	2026-09-28
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma Intratumoral 2141-V11, Nivolumab, Fluoropyrimidine - Esophageal Cancer, Advanced Esophageal Cancer	Phase 1 / Phase 2	Recruiting	Memorial Sloan Kettering Cancer Center	30	2026-09-04	2026-09-14

Showing 20 of 2311. Sign in to see all of them.

Narrower conditions

Esophageal Squamous Cell Carcinoma (622)  ·  Stomach Neoplasms (571)  ·  Pancreatic Neoplasms (247)  ·  Carcinoma, Non-Small-Cell Lung (225)  ·  Adenocarcinoma Of Esophagus (205)  ·  Lung Neoplasms (203)  ·  Colorectal Neoplasms (200)  ·  Breast Neoplasms (177)  ·  Ovarian Neoplasms (160)  ·  Neoplasms (149)  ·  Head and Neck Neoplasms (141)  ·  Uterine Cervical Neoplasms (141)  ·  Colonic Neoplasms (124)  ·  Urinary Bladder Neoplasms (123)

Broader conditions

Digestive System Diseases (2303)  ·  Neoplasms by Site (2303)  ·  Digestive System Neoplasms (2299)  ·  Gastrointestinal Diseases (2299)  ·  Esophageal Diseases (2291)  ·  Gastrointestinal Neoplasms (2252)  ·  Head and Neck Neoplasms (2170)  ·  Neoplasms (2162)  ·  Neoplasms by Histologic Type (963)  ·  Neoplasms, Glandular and Epithelial (910)  ·  Carcinoma (858)  ·  Carcinoma, Squamous Cell (676)  ·  Neoplasms, Squamous Cell (647)  ·  Stomach Diseases (573)

Interventions

Cisplatin (238)  ·  Paclitaxel (181)  ·  Radiotherapy (174)  ·  Fluorouracil (165)  ·  Carboplatin (110)  ·  Oxaliplatin (100)  ·  pembrolizumab (89)  ·  Docetaxel (86)  ·  Irinotecan (78)  ·  Drug Therapy (72)  ·  Capecitabine (70)  ·  Leucovorin (64)  ·  Radiation (61)  ·  Esophagectomy (58)  ·  Surgical Procedures, Operative (51)

Sponsors

Fudan University (54)  ·  National Cancer Institute (NCI) (48)  ·  Sun Yat-sen University (47)  ·  Memorial Sloan Kettering Cancer Center (41)  ·  Tianjin Medical University Cancer Institute and Hospital (33)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (29)  ·  M.D. Anderson Cancer Center (29)  ·  National Taiwan University Hospital (28)  ·  Chinese Academy of Medical Sciences (27)  ·  Alliance for Clinical Trials in Oncology (22)  ·  Shanghai Chest Hospital (22)  ·  Henan Cancer Hospital (21)  ·  Zhejiang Cancer Hospital (21)  ·  Peking University (20)  ·  Shanghai Zhongshan Hospital (20)

Countries

China (793)  ·  United States (740)  ·  United Kingdom (131)  ·  France (122)  ·  Taiwan (107)  ·  Germany (99)  ·  Netherlands (96)  ·  South Korea (95)  ·  Canada (91)  ·  Japan (85)  ·  Spain (81)  ·  Italy (67)  ·  Belgium (58)  ·  Australia (52)  ·  Denmark (39)

Top investigators

David H. Ilson, MD, PhD (11)  ·  Aminah Jatoi, MD (8)  ·  David S Schrump, M.D. (8)  ·  Feng Wang (7)  ·  Lin Shen, MD (7)  ·  Yelena Janjigian, MD (7)  ·  Peter Enzinger, MD (6)  ·  Zefen Xiao, MD (6)

Results publications

PMID 33538338, PMID 22646630, PMID 26808342, PMID 36990609, PMID 26254683, PMID 30089078, PMID 18309943, PMID 21684205, PMID 26313683, PMID 33373868, PMID 34454674, PMID 35623069, PMID 41309527, PMID 10235156, PMID 11208820, PMID 11870157, PMID 19465425, PMID 21839994, PMID 23148692, PMID 24224128, PMID 24371038, PMID 24612702, PMID 24982463, PMID 25668428, PMID 25691612, PMID 26805559, PMID 27223606, PMID 27266524, PMID 27742014, PMID 28742685, PMID 29799976, PMID 30207593, PMID 30291834, PMID 30308612, PMID 32768158, PMID 33026938, PMID 33553366, PMID 33674602, PMID 33813524, PMID 34160577, PMID 34351356, PMID 35440464, PMID 36812121, PMID 37139963, PMID 37195667, PMID 37488287, PMID 37496366, PMID 37932848, PMID 38710003, PMID 39221992

NIH funding

2023 (21), 2019 (11), 2017 (9), 2014 (5), 2015 (5), 2018 (5), P30CA008748 (5), P30CA043703 (5), P30CA068485 (5), U10CA032102 (5), 2016 (4), 2025 (4), U10CA021115 (4), P30CA015083 (3), P30CA016056 (3)